title: Accelerated conversion of dehydroepiandrosterone sulfate to estrogen in a patient with Crow-Fukase syndrome and diabetes mellitus.
abstract: About 28% of patients with the Crow-Fukase syndrome exhibit glucose intolerance which may be induced by low serum levels of dehydroepiandrosterone (DHEA). We report a patient with the Crow-Fukase syndrome who exhibited non-insulin dependent diabetes mellitus (NIDDM) worsened prior to admission. He received the DHEA sulfate (DHEA-S) infusion test to evaluate aromatase activity. This patient exhibited an increase in aromatase activity measured by the conversion of the intravenously loaded DHEA-S to estrogen, and low serum levels of DHEA and DHEA-S. These abnormalities returned to nearly normal during the administration of prednisolone, 60 mg per day. No adverse effect on his diabetes was observed during the corticosteroid treatment. Five control patients with diabetes but without the Crow-Fukase syndrome showed no increase in the conversion of DHEA-S to estrogen, which suggests that aromatase activity is normal in diabetes. The increase in aromatase activity in our patient may have led to a low serum concentration of DHEA that in turn caused glucose intolerance and a deterioration of the diabetes prior to admission. Glucocorticoid therapy may be beneficial in Crow-Fukase syndrome to improve the distorted metabolism of DHEA with no adverse effect on the diabetes.
authors.affiliation: Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Sichi, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mano
authors.forename: K
authors.initials: K
authors.lastname: Mori
authors.forename: Y
authors.initials: Y
authors.lastname: Sawai
authors.forename: N
authors.initials: N
authors.lastname: Oda
authors.forename: T
authors.initials: T
authors.lastname: Tugawa
authors.forename: I
authors.initials: I
authors.lastname: Nakano
authors.forename: F
authors.initials: F
authors.lastname: Watanabe
authors.forename: M
authors.initials: M
authors.lastname: Hamada
authors.forename: A
authors.initials: A
authors.lastname: Nakai
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
authors.forename: N
authors.initials: N
authors.lastname: Harada
authors.forename: A
authors.initials: A
authors.lastname: Nagasaka
authors.forename: M
authors.initials: M
authors.lastname: Itoh
mesh_terms: D001141:Aromatase / Q000235:genetics / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D003687:Dehydroepiandrosterone / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000097:blood*; D004970:Estrone / Q000097:blood; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D016878:POEMS Syndrome / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D011239:Prednisolone / Q000627:therapeutic use; D012333:RNA, Messenger / Q000032:analysis; D013739:Testosterone / Q000097:blood
chemical_list: D001141:Aromatase; D001786:Blood Glucose; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D004958:Estradiol; D004967:Estrogens; D004970:Estrone; D006442:Glycated Hemoglobin; D011239:Prednisolone; D012333:RNA, Messenger; D013739:Testosterone